Zivo Bioscience, Inc. (ZIVO)
ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods. The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being. Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014. Its corporate operations are based in Bloomfield Hills, Michigan.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
ZIVO Bioscience, Inc.
- Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
- 7.7K
- 8.49
The cost to borrow ZIVO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 30.5%
- 40
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 7.7K sh |
| Oct 15, 2026 | 7.9K sh |
| Sep 30, 2026 | 8.0K sh |
| Sep 15, 2026 | 8.0K sh |
| Aug 31, 2026 | 7.8K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 13, 2026 | 40 sh |
| Jul 24, 2026 | 4 sh |
| Jul 6, 2026 | 76 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 30.5% |
| Nov 16, 2026 | 42.9% |
| Nov 9, 2026 | 2.9% |
| Nov 6, 2026 | 100.0% |
| Nov 4, 2026 | 11.5% |
130 calendar days requested; 27 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for ZIVO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 7,729 ZIVO shares were sold short (8.49 days to cover).